请输入关键字
请输入关键字
订购
*国家
中国
美国
中国香港
中国澳门
中国台湾
阿尔巴尼亚
阿尔及利亚
阿根廷
阿拉伯联合酋长国
阿鲁巴
阿曼
阿塞拜疆
阿森松岛
埃及
埃塞俄比亚
爱尔兰
爱沙尼亚
安道尔
安哥拉
安圭拉
安提瓜和巴布达
奥地利
奥兰群岛
澳大利亚
巴巴多斯
巴布亚新几内亚
巴哈马
巴基斯坦
巴拉圭
巴勒斯坦领土
巴林
巴拿马
巴西
白俄罗斯
百慕大
保加利亚
北马里亚纳群岛
贝宁
比利时
冰岛
波多黎各
波兰
波斯尼亚和黑塞哥维那
玻利维亚
伯利兹
博茨瓦纳
不丹
布基纳法索
布隆迪
朝鲜
赤道几内亚
丹麦
德国
迪戈加西亚岛
东帝汶
多哥
多米尼加共和国
多米尼克
俄罗斯
厄瓜多尔
厄立特里亚
法国
法罗群岛
法属波利尼西亚
法属圭亚那
法属南部领地
梵蒂冈
菲律宾
斐济
芬兰
佛得角
福克兰群岛
冈比亚
刚果(布)
刚果(金)
哥伦比亚
哥斯达黎加
格恩西岛
格林纳达
格陵兰
格鲁吉亚
古巴
瓜德罗普
关岛
圭亚那
哈萨克斯坦
海地
韩国
荷兰
荷属加勒比区
荷属圣马丁
黑山
洪都拉斯
基里巴斯
吉布提
吉尔吉斯斯坦
几内亚
几内亚比绍
加拿大
加纳
加纳利群岛
加蓬
柬埔寨
捷克
津巴布韦
喀麦隆
卡塔尔
开曼群岛
科科斯(基林)群岛
科摩罗
科索沃
科特迪瓦
科威特
克罗地亚
肯尼亚
库克群岛
库拉索
拉脱维亚
莱索托
老挝
黎巴嫩
立陶宛
利比里亚
利比亚
联合国
列支敦士登
留尼汪
卢森堡
卢旺达
罗马尼亚
马达加斯加
马恩岛
马尔代夫
马耳他
马拉维
马来西亚
马里
马其顿
马绍尔群岛
马提尼克
马约特
毛里求斯
毛里塔尼亚
美国本土外小岛屿
美属萨摩亚
美属维尔京群岛
蒙古
蒙特塞拉特
孟加拉国
秘鲁
密克罗尼西亚
缅甸
摩尔多瓦
摩洛哥
摩纳哥
莫桑比克
墨西哥
纳米比亚
南非
南极洲
南乔治亚和南桑威奇群岛
南苏丹
瑙鲁
尼加拉瓜
尼泊尔
尼日尔
尼日利亚
纽埃
挪威
诺福克岛
帕劳
皮特凯恩群岛
葡萄牙
日本
瑞典
瑞士
萨尔瓦多
萨摩亚
塞尔维亚
塞拉利昂
塞内加尔
塞浦路斯
塞舌尔
沙特阿拉伯
圣巴泰勒米
圣诞岛
圣多美和普林西比
圣赫勒拿
圣基茨和尼维斯
圣卢西亚
圣马丁岛
圣马力诺
圣皮埃尔和密克隆群岛
圣文森特和格林纳丁斯
斯里兰卡
斯洛伐克
斯洛文尼亚
斯瓦尔巴和扬马延
斯威士兰
苏丹
苏里南
所罗门群岛
索马里
塔吉克斯坦
泰国
坦桑尼亚
汤加
特克斯和凯科斯群岛
特里斯坦-达库尼亚群岛
特立尼达和多巴哥
突尼斯
图瓦卢
土耳其
土库曼斯坦
托克劳
瓦利斯和富图纳
瓦努阿图
危地马拉
委内瑞拉
文莱
乌干达
乌克兰
乌拉圭
乌兹别克斯坦
希腊
西班牙
西撒哈拉
新加坡
新喀里多尼亚
新西兰
匈牙利
休达及梅利利亚
叙利亚
牙买加
亚美尼亚
也门
伊拉克
伊朗
以色列
意大利
印度
印度尼西亚
英国
英属维尔京群岛
英属印度洋领地
约旦
越南
赞比亚
泽西岛
乍得
直布罗陀
智利
中非共和国
*省份
*城市
*姓名
*电话
*单位
*职位
*邮箱
*请输入验证码
*验证码
B-SDG rats
Strain Name 

SD-Rag2tm1Bcgen Il2rgtm1Bcgen/Bcgen


Common Name 

B-SDG rats

Background SD Catalog number 210512
Aliases 

Rag2: RAG-2; 
Il2rg: CD132, [g]c, gamma(c), gc, p64

NCBI Gene ID
295953,140924

B-SDG rats exhibit the smallest thymus size


from clipboard


The thymus size of B-SDG rats was the smallest compared to that of wild-type SD rats and B-Rag2 KO rats. Gross anatomy of thymuses in male and female wild-type SD rats, B-Rag2 KO rats and B-SDG rats were showed (n=3, 7-week-old). Thymus size of B-Rag2 KO rats were significantly reduced compared to that of wild-type SD rats. But the thymus size of B-SDG rats were further reduced compared to B-Rag2 KO rats. 

B-SDG rats exhibit the significantly reduced thymus and spleen weight 

from clipboard


The size and weight of thymus and spleen of B-SDG rats were significantly reduced compared to that of wild-type SD rats. Thymus and spleen were isolated from male and female wild-type SD rats, B-Rag2 KO rats and B-SDG rats and weighed (n=3, 7-week-old). Thymus size and weight of B-Rag2 KO rats were significantly reduced compared to that of wild-type SD rats. But the thymus size and weight of B-SDG rats were further reduced compared to B-Rag2 KO rats. Spleen size and weight of B-Rag2 KO rats and B-SDG rats were significantly reduced compared to that of wild-type SD rats. 

Analysis of leukocyte subpopulation in thymus

from clipboard


Complete loss of T cells in thymus of homozygous B-Rag2 KO rats and B-SDG rats. Thymuses were collected from male and female wild-type SD rats, B-Rag2 KO rats and B-SDG rats (n=3, 7-week-old). Leukocyte subpopulations were analyzed by flow cytometry analysis. A. Representative FACS plots. B. Statistical analysis of FACS. Results showed that total T cells, CD4+ T cells and CD8+ T cells were only detectable in thymuses of wild-type SD rats. But none of the T cells were detectable in thymuses of B-Rag2 KO rats or B-SDG rats. Values are expressed as mean ± SEM.

Analysis of leukocyte subpopulation in spleen of male rats

from clipboard


Complete loss of T cells, B cells and NK cells in spleen of homozygous male B-SDG rats. Spleens were collected from male wild-type SD rats, B-Rag2 KO rats and B-SDG rats (n=3, 7-week-old). Leukocyte subpopulations were analyzed by flow cytometry analysis. Results showed that T cells and B cells were not detectable in spleen of B-Rag2 KO rats and B-SDG rats. NK cells were also not detectable in B-SDG rats. But the percentage of NK cells in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. The percentages of DCs, CD11b+CD43+ monocytes, CD11b+CD68+ macrophages, CD11b+CD43+CD68+ monocytes/macrophages (Mo/Mφ) and neutrophils in B-Rag2 KO rats and B-SDG rats were relatively higher than that in wild-type SD rats. Values are expressed as mean ± SEM.

Analysis of leukocyte subpopulation in spleen of female rats

from clipboard


Complete loss of T cells, B cells and NK cells in spleen of homozygous female B-SDG rats. Spleens were collected from female wild-type SD rats, B-Rag2 KO rats and B-SDG rats (n=3, 7-week-old). Leukocyte subpopulations were analyzed by flow cytometry analysis. Results showed that T cells and B cells were not detectable in spleen of B-Rag2 KO rats and B-SDG rats. NK cells were also not detectable in B-SDG rats. But the percentage of NK cells in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. The percentages of DCs, CD11b+CD43+ monocytes, CD11b+CD68+ macrophages, CD11b+CD43+CD68+ monocytes/macrophages (Mo/Mφ) and neutrophils in B-Rag2 KO rats and B-SDG rats were relatively higher than that in wild-type SD rats. Values are expressed as mean ± SEM.

Analysis of leukocyte subpopulation in spleen

from clipboard

Complete loss of T cells, B cells and NK cells in spleen of homozygous male and female B-SDG rats. Spleens were collected from male and female wild-type SD rats, B-Rag2 KO rats and B-SDG rats (n=3, 7-week-old). Leukocyte subpopulations were analyzed by flow cytometry analysis. Results showed that T cells and B cells were not detectable in spleen of B-Rag2 KO rats and B-SDG rats. NK cells were also not detectable in B-SDG rats. But the percentage of NK cells in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. The percentages of DCs, CD11b+CD43+ monocytes, CD11b+CD68+ macrophages, CD11b+CD43+CD68+ monocytes/macrophages (Mo/Mφ) and neutrophils in B-Rag2 KO rats and B-SDG rats were relatively higher than that in wild-type SD rats. Values are expressed as mean ± SEM.


Analysis of leukocyte subpopulation in blood of male rats

from clipboard


Complete loss of T cells, B cells and NK cells in blood of homozygous male B-SDG rats. Blood cells were collected from male wild-type SD rats, B-Rag2 KO rats and B-SDG rats (n=3, 7-week-old). Leukocyte subpopulations were analyzed by flow cytometry analysis. Results showed that T cells and B cells were not detectable in blood of B-Rag2 KO rats and B-SDG rats. NK cells were also not detectable in B-SDG rats. But the percentage of NK cells in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. The percentages of DCs, CD11b+CD43+ monocytes, CD11b+CD68+ macrophages, CD11b+CD43+CD68+ monocytes/macrophages (Mo/Mφ) and neutrophils in B-Rag2 KO rats and B-SDG rats were relatively higher than that in wild-type SD rats. Values are expressed as mean ± SEM.

Analysis of leukocyte subpopulation in blood of female rats

from clipboard


Complete loss of T cells, B cells and NK cells in blood of homozygous female B-SDG rats. Blood cells were collected from female wild-type SD rats, B-Rag2 KO rats and B-SDG rats (n=3, 7-week-old). Leukocyte subpopulations were analyzed by flow cytometry analysis. Results showed that T cells and B cells were not detectable in blood of B-Rag2 KO rats and B-SDG rats. NK cells were also not detectable in B-SDG rats. But the percentage of NK cells in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. The percentages of DCs, CD11b+CD43+ monocytes, CD11b+CD68+ macrophages, CD11b+CD43+CD68+ monocytes/macrophages (Mo/Mφ) and neutrophils in B-Rag2 KO rats and B-SDG rats were relatively higher than that in wild-type SD rats. Values are expressed as mean ± SEM.

Analysis of leukocyte subpopulation in blood

from clipboard

Complete loss of T cells, B cells and NK cells in blood of homozygous male and female B-SDG rats. Blood cells were collected from male and female wild-type SD rats, B-Rag2 KO rats and B-SDG rats (n=3, 7-week-old). Leukocyte subpopulations were analyzed by flow cytometry analysis. A. Representative FACS plots. B. Statistical analysis of FACS. Results showed that T cells and B cells were not detectable in blood of B-Rag2 KO rats and B-SDG rats. NK cells were also not detectable in B-SDG rats. But the percentage of NK cells in B-Rag2 KO rats were relatively higher than that in wild-type SD rats. The percentages of DCs, CD11b+CD43+ monocytes, CD11b+CD68+ macrophages, CD11b+CD43+CD68+ monocytes/macrophages (Mo/Mφ) and neutrophils in B-Rag2 KO rats and B-SDG rats were relatively higher than that in wild-type SD rats. Values are expressed as mean ± SEM.


Growth curve 



from clipboard

Growth curve of B-SDG rats.Three weeks old of newborn pups were obtained at weaning. Body weight of the rats with ages from 3 weeks to 15 weeks was measured (male: n=14~21; female: n=21~30). The lowest and highest values of the body weight in the table were calculated from the mean ± SD. The growth curve conforms to the normal distribution and the probability of random error falling within ± SD is 68%.


NCI-H460 human large cell lung cancer xenograft model in B-SDG rats


from clipboard

Subcutaneous homograft tumor growth of NCI-H460 cells in B-SDG rats. Human large cell lung cancer cell line NCI-H460 were mixed with Matrigel (1:1, Corning, 354230) and inoculated subcutaneously into B-SDG rats (female, 9-week-old, n=6). (A)Tumor volume. (B) Body weight change. As shown in panel A, NCI-H460 cells were able to establish tumors in B-SDG rats, and this strain of rat can be used for efficacy studies. 


MIA PaCa-2 human pancreas cancer xenograft model in B-SDG rats

from clipboard

Subcutaneous homograft tumor growth of MIA PaCa-2 cells in B-SDG rats. Human pancreas cancer cell line MIA PaCa-2 (2x107) were mixed with Matrigel (1:1, Corning, 354230) and inoculated subcutaneously into B-SDG rats (n=6). (A)Tumor volume. (B) Body weight. As shown in panel A, MIA PaCa-2 cells were able to establish tumors in B-SDG rats and B-Rag2 KO rats, and the two strains of rats can be used for efficacy studies.  


In vivo efficacy of cisplatin evaluated with B-SDG rats


from clipboard

Antitumor activity of cisplatin in B-SDG rats. (A) Cisplatin inhibited HCC1954 tumor growth in B-SDG rats. Human breast invasive ductal carcinoma cell line HCC1954  (2E7) mixed with Matrigel (1:1, Corning, 354230) were subcutaneously implanted into B-SDG rats (female, 9-week-old, n=6). The rats were grouped when tumor volume reached approximately 300-400 mm3, at which time they were treated with cisplatin with doses indicated in panel. (B) Body weight changes during treatment. As shown in panel A, cisplatin was efficacious in controlling tumor growth in B-SDG rats, demonstrating that B-SDG rats provide a powerful preclinical model for in vivo evaluation of chemotherapies. Values are expressed as mean ± SEM. 

In vivo efficacy of cisplatin evaluated with B-SDG rats 


from clipboard

Antitumor activity of cisplatin in B-SDG rats. (A) Cisplatin inhibited NCI-H460 tumor growth in B-SDG rats. Human large cell lung cancer cell line NCI-H460 (2E6) mixed with Matrigel (1:1, Corning, 354230) were subcutaneously implanted into B-SDG rats (female, 9-week-old, n=6). The rats were grouped when tumor volume reached approximately 300-400 mm3, at which time they were treated with cisplatin with the dose indicated in panel. (B) Body weight changes during treatment. As shown in panel A, cisplatin was efficacious in controlling tumor growth in B-SDG rats, demonstrating that B-SDG rats provide a powerful preclinical model for in vivo evaluation of chemotherapies. Values are expressed as mean ± SEM.


In vivo efficacy of Her2-targeting ADC drug evaluated with B-SDG rats  

from clipboard

Antitumor activity of Her2-targeting ADC drug in B-SDG rats. Human non-small cell lung cancer cell line NCI-H1975 (5×106) mixed with Matrigel (1:1, Corning, 354230) were subcutaneously implanted into B-SDG rats (female, 8-week-old, n=6). The rats were grouped when tumor volume reached approximately 300-400 mm3, at which time they were treated with trastuzumab-VcMMAE analog (in-house). Blood was collected at 15 min, 24 hr and 96 hr after the first two doses from every mouse. After the third dose, the time points of blood collection were 15 min, 24 hr, 96 hr and 168 hr. (A) Trastuzumab-VcMMAE analog (in-house) inhibited the growth of NCI-H1975 in B-SDG rats. (B) Body weight changes during treatment. (C) Time course of drug concentration in blood. Results showed that Her2-targeting ADC drug was efficacious in controlling tumor growth in B-SDG rats in a dose-dependent manner. The drug concentration was maintained at a steady high level in the high dosing group. There is a significant correlation between the efficacy and drug concentration. Therefore, B-SDG rats provide a powerful preclinical model for in vivo efficacy evaluation and pharmacokinetics study of ADC drugs. Values are expressed as mean ± SEM.